Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral TTI-621 in Advanced Solid Tumors and Mycosis Fungoides
NCT02890368Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Mar 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of maplirpacept in solid tumor, mycosis fungoides (MF), melanoma and 5 more (7 arms), sponsored by Pfizer. Primary endpoint: Optimal TTI-621 delivery regimen at 10 months. Started Sep 2016; status: terminated.
02
Drugs
maplirpacept
03
Conditions
solid tumormycosis fungoides (MF)melanomaMerkel cell carcinoma (MCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT02890368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890368.